Biofilm inhibiting compositions enhancing weight gain in livestock

• US 10,377,785 B2
• Filed: 08/03/2018
• Issued: 08/13/2019
• Est. Priority Date: 08/11/2015
• Status: Expired due to Fees

• Current Assignee: Akeso Biomedical, Inc.
• Original Assignee: Akeso Biomedical, Inc.
• Inventors: Ala'Aldeen, Dlawer, Mahdavi, Jafar, Soultanas, Panos
• Primary Examiner(s): Kosack, Joseph R
• Application Number:
  US16/054,713
• Publication Number:
  US 20180340003A1
• Time in Patent Office: 375 Days
• CPC Class Codes: A01N 37/10 Aromatic or araliphatic carboxylic acids, or thio analogues thereof; Derivatives thereof
• CPC Class Codes: A01N 37/36 containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids
• CPC Class Codes: A01N 37/44 containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
• CPC Class Codes: A01N 59/16 Heavy metals; Compounds thereof
• CPC Class Codes: A23K 20/195 Antibiotics
• CPC Class Codes: A23K 20/30 Oligoelements
• CPC Class Codes: A23K 50/10 for ruminants
• CPC Class Codes: A23K 50/30 for swines
• CPC Class Codes: A23K 50/60 for weanlings
• CPC Class Codes: A23K 50/75 for poultry
• CPC Class Codes: A23L 33/127 Antibiotics
• CPC Class Codes: A23L 33/16 Inorganic salts, minerals or trace elements
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A61K 31/197 the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid carnitine A61K31/205
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/295 Iron group metal compounds
• CPC Class Codes: A61K 31/7036 having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61L 12/08 using chemical substances
• CPC Class Codes: A61L 2/0088 Liquid substances
• CPC Class Codes: A61L 2/16 : using chemical substances
• CPC Class Codes: A61L 2/18 : Liquid substances or solutions comprising solids or dissolved gases
• CPC Class Codes: A61L 2/22 : Phase substances, e.g. smokes, aerosols or sprayed or atomised substances
• CPC Class Codes: A61L 2202/24 : Medical instruments, e.g. endoscopes, catheters, sharps
• CPC Class Codes: A61P 31/00 : Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: C07F 15/025 : without a metal-carbon linkage
• CPC Class Codes: C09D 5/14 : Paints containing biocides, e.g. fungicides, insecticides or pesticides C09D5/16 takes precedence
• CPC Class Codes: G02B 1/043 : Contact lenses
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A method of enhancing the growth of an animal, as well as treating or preventing antimicrobial infections is provided. The method includes causing the animal to ingest or absorb an effective amount of one or more Fe III complex compounds, including but not limited to Fe III complexes comprising ligands bound to the iron center such as amino acids or α-hydroxy acids. The compounds are also useful for inhibiting, reducing, or preventing biofilm formation or buildup on a surface; the treatment of, inhibition of growth of, and inhibition of colonization by, bacteria, both in biological and non-biological environments; disinfecting surfaces, potentiating the effects of antibiotics and other anti-microbial agents, and increasing the sensitivity of bacteria and other microorganisms, to anti-microbial agents are also provided.

Claims

1. A method for the treatment or prophylaxis of a microbial infection or colonization in a human, the method comprising administering to the human—

an effective amount of a composition comprising one or more Fe III complexes to reduce enteropathogen infection in the human, wherein the Fe III complex is a compound of Formula I;

Fe(III)x(ligand)y 

 

Formula I,

wherein

x is an integer value of 1-2,

y is an integer value of 1-3 and

wherein the Fe III complexes comprise Fe III and one or more ligands,

wherein each ligand is independently a conjugate base of an α

-hydroxy acid selected from citric acid, tartaric acid, lactic acid, glycolic acid, quinic acid, glycolic acid, isoleucic acid, valic acid, malic acid, and mandelic acid;

or each ligand is a conjugate base of an amino acid independently selected from the group consisting of glycine, alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine; and

salts and/or hydrates thereof,

and wherein at least one of the one or more Fe III complexes is in a concentrations ranging from 10 μ

M to 2 mM or 0.01 g/Kg of product to 20 g/Kg of product.

2. The method of claim 1, wherein the human is infected with one or more microorganisms selected from the group consisting of Actinobacillus, Bordetalla, Campylobacter, Clostridium, Corynebacterium, Escherichia coli, Globicatella, Listeria, Mycobacterium, Salmonella, Staphylococcus, and Streptococcus.

3. The method of claim 2, wherein the microbial infection is caused by a microorganism selected from the group consisting of a S. epidermidis, E. faecalis, E. coli, S. aureus including Vancomycin-resistant Staphylococcus aureus (VRSA) and Methicillin-resistant Staphylococcus aureus (MRSA), Enteropathogenic Escherichia coli (EPEC), Uropathogenic Escherichia coli (UPEC), Pseudomonas, Streptococcus pneumoniae, Streptococcus anginosus, Neisseria gonorrhoeae, Salmonella Salmonella Enteritidis, Salmonella Typhimurium, Mycoplasma, Eimeria, Enterococci, Shigella, Vancomycin-resistant Enterococcus (VRE), Erythromycin-resistant Group A Streptococcus, Clindamycin-resistant Group B Streptococcus, Carbapenem-resistant Enterobacteriaceae (CRE), drug-resistant tuberculosis, Extended spectrum Enterobacteriaceae (ESBL), multidrug-resistant Acinetobacter, Clostridium difficile, Enteropathogenic E. coli (EPEC), Pseudomonas aeruginosa, Brachyspira, Propionibacterium acnes, and Clostridium perfringen.

4. The method of claim 1, wherein the Fe III complex is ferric citrate.

5. The method of claim 1, wherein each ligand is an amino acid independently selected from the group consisting of glycine, alanine, aspartic acid, cysteine, glutamic acid, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tyrosine, and valine.

6. The method of claim 1, wherein the concentration of the compound is between 10 μ

M and 500 μ

M.

7. The method of claim 1 wherein the product is topical formulation, including as an emulsion, lotion, cream, ointment, gel, or foam.

8. The method of claim 7, wherein the compound is effective to reduce biofilms formed on the skin.

9. The method of claim 8, wherein the biofilm comprise Propionibacterium acnes.

10. The method of claim 3, wherein the human subject is infected with Clostridium difficile, Pseudomonas aeruginosa, and Campylobacter jejuni.